Elite in Mucopolysaccharidosis Type 1 (MPS I, Hurler Syndrome)

Bernhard Gentner

Lausanne Branch, 
Lausanne, VD, CH 
Elite in Mucopolysaccharidosis Type 1 (MPS I, Hurler Syndrome)
Lausanne Branch, 
Lausanne, VD, CH 
OverviewLocationsClinical Research

Overview

Bernhard Gentner practices in Lausanne, Switzerland. Mr. Gentner is rated as an Elite expert by MediFind in the treatment of Mucopolysaccharidosis Type 1 (MPS I, Hurler Syndrome). His top areas of expertise are Mucopolysaccharidosis Type 1 (MPS I, Hurler Syndrome), Mucopolysaccharidoses (MPS), Leukemia, Glioblastoma, and Bone Marrow Transplant.

His clinical research consists of co-authoring 66 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 6 articles and participated in 1 clinical trial in the study of Mucopolysaccharidosis Type 1 (MPS I, Hurler Syndrome).

Gender
Male

Locations

Lausanne Branch, Lausanne, VD, Switzerland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

Phase I/II Study Evaluating Safety and Efficacy of Autologous Hematopoietic Stem and Progenitor Cells Genetically Modified With IDUA Lentiviral Vector Encoding for the Human α-L-iduronidase Gene for the Treatment of Patients Affected by Mucopolysaccharidosis Type I, Hurler Variant
Phase I/II Study Evaluating Safety and Efficacy of Autologous Hematopoietic Stem and Progenitor Cells Genetically Modified With IDUA Lentiviral Vector Encoding for the Human α-L-iduronidase Gene for the Treatment of Patients Affected by Mucopolysaccharidosis Type I, Hurler Variant
Enrollment Status: Active_not_recruiting
Publish Date: July 29, 2025
Intervention Type: Genetic
Study Phase: Phase 1/Phase 2

66 Total Publications

A cross-talk established by tumor-targeted cytokines rescues CAR T cell activity and engages host T cells against glioblastoma in mice.
A cross-talk established by tumor-targeted cytokines rescues CAR T cell activity and engages host T cells against glioblastoma in mice.
Journal: Science translational medicine
Published: July 02, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Gentner's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 23 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile